NeoTYPE Cancer Profiles Multimethod Analysis of 25+ Hematologic Diseases and Solid Tumors Anatomic Pathology FISH Molecular The next generation of diagnostic, prognostic, and therapeutic assessment
NeoTYPE Cancer Profiles are multi-method test panels based on next-gen sequencing that identify the genetic changes most significant for Confirming diagnosis Disease classification Assessing prognosis Predicting response to therapy Identifying new therapeutic approaches Identifying clinical trial opportunities When to test These Profiles highlight high-frequency recurrent mutations and provide a practical approach to understanding the cancer s biology for the most effective patient management. Tests are appropriate for: First-line gene testing Patients with an unusual clinical presentation Developing therapeutic strategies Identifying clinical trials Patients resistant to conventional therapy 2 NeoGenomics Laboratories
Benefits and Advantages of Targeted Profile Testing Targeted Test design is tailored to driver mutations in specific tumors. Actionable All genes have clinical significance when mutated. Comprehensive Unique reporting of diagnostic, prognostic, and therapeutic implications. Flexible Choose as-shown or as add on. Efficient With fast TAT s, NeoTYPEs can replace first-line single-gene testing. Quantitative Reporting of mutant allele frequencies is useful for monitoring. Cost-effective Flexibility, Performance, Selection Next-generation sequencing (NGS) is widely known for its high sensitivity which aids detection of abnormalities in small biopsies, minimal residual disease, and subclonal heterogeneity. The NeoTYPE next-gen suite offers an additional set of distinct benefits focusing on driver genes and actionable abnormalities, which includes point mutations, indels, translocations, and more. NeoTYPE Cancer Profiles simplify the laboratory testing process and provide key diagnostic, prognostic, and predictive information you need for up-to-date and fully informed decision-making. NeoGenomics Laboratories 3
Sa m pl e Sample Report 4 NeoGenomics Laboratories
Broad Reach Hematologic Profiles Myeloid Disorders (54 Molecular) ABL1 ASXL1 ATRX BCOR BCORL1 CALR CBL CBLB CBLC CDKN2A CSF3R CUX1 DNMT3A ETV6 EZH2 FBXW7 GATA1 GATA2 GNAS IKZF1 JAK2 V617F JAK2 Exon 12+14 KDM6A MLL MPL MYD88 PHF6 RAD21 RUNX1 SF3B1 SMC1A SMC3 SRSF2 STAG2 TET2 U2AF1 WT1 ZRSR2 Broad Reach Solid Tumor Profiles Precision (48 Molecular, 1 IHC) ABL1 ALK APC ATM CDH1 CDKN2A CSF1R FBXW7 GNA11 GNAQ GNAS HNF1A JAK2 KDR MLH1 MPL RB1 RET SMARCB1 STK11 VHL Discovery (315 Molecular, 9 FISH, 1 IHC) Next-gen sequencing of 315 genes + 9 FISH +. This is an actionable discovery panel suitable for clinical research applications and widespectrum patient testing. See website or handout for complete test details. Cancer Exome (4813 Molecular) Next-gen sequencing of 4813 cancer-related genes. Testing is recommended for those interested in academic or clinical research. See website for complete test details, or call our Client Services Team at 866.776.5907. Cancer-Specific Hematologic Profiles AITL/Peripheral T-Cell Lymphoma Profile (5 Molecular) DNMT3A RHOA TET2 AML Favorable-Risk (2 Molecular) AML Prognostic (27 Molecular) ASXL1 BCOR CSF3R DNMT3A ETV6 EZH2 JAK2 MLL PHF6 RUNX1 STAG2 TET2 WT1 CLL Prognostic (5 Molecular, 1 FISH Panel) IgVH Mutation MYD88 SF3B1 CLL FISH Panel JMML (16 Molecular) CBL JAK2 V617F JAK2 Exon 12+14 Lymphoma (8 Molecular) BCL1 BCL2 CARD11 CD79B EZH2 MYD88 MDS/CMML (32 Molecular) ASXL1 BCOR BCORL1 CBL CUX1 DNMT3A ETV6 EZH2 JAK2 V617F JAK2 Exon 12+14 RUNX1 SF3B1 SRSF2 STAG2 TET2 U2AF1 ZRSR2 MPN (25 Molecular) ABL1 ASXL1 CALR CSF3R EZH2 JAK2 V617F JAK2 Exon 12+14 MPL SRSF2 TET2 U2AF1 NeoGenomics Laboratories 5
Cancer-Specific Solid Tumor Profiles Brain (22 Molecular, 5 FISH, 1 IHC) ATRX vlll Analysis MGMT Promoter Methylation TERT Promoter 1p/19q Deletion FISH FISH FISH MYCN FISH FISH Breast (22 Molecular, 3 FISH, 1 IHC) BRCA1 BRCA2 FISH FISH Cervical (22 Molecular, 2 FISH, 1 IHC) FISH FISH Colorectal (24 Molecular, 2 FISH, 1 IHC) APC Microsatellite Instability (MSI) MLH1 Promoter Methylation FISH FISH Endometrial (21 Molecular, 2 FISH, 1 IHC) Microsatellite Instability (MSI) FISH FISH Esophageal (22 Molecular, 3 FISH, 1 IHC) FISH FISH Gastric (22 Molecular, 3 FISH, 1 IHC) FISH FISH GIST (11 Molecular, 1 IHC) Head & Neck (25 Molecular, 2 FISH, 1 IHC) ATM CDKN2A RB FISH FISH HPV DNA Tissue Test Liver/Biliary (24 Molecular, 2 FISH, 1 IHC) ATM CDKN2A FISH FISH Liposarcoma Fusion Profile (5 Molecular, 1 FISH) COL1A2-PLAG1 EWSR1-DDIT3 FUS-DDIT3 HMGA2-LPP LPP-HMGA2 MDM2 FISH NeoGenomics Laboratories 6
Lung (21 Molecular, 6 FISH, 1 IHC) Exon 14 Deletion Analysis ALK FISH FISH FISH RET FISH ROS1 FISH Melanoma (17 Molecular, 1 FISH, 1 IHC) GNAQ TERT Promoter FISH Other Solid Tumor (24 Molecular, 2 FISH, 1 IHC) GNAS FISH FISH Ovarian (22 Molecular, 2 FISH, 1 IHC) BRCA1 BRCA2 FISH FISH Pancreas (22 Molecular, 3 FISH, 1 IHC) BRCA1 BRCA2 FISH FISH Soft Tissue (19 Molecular, 2 FISH, 1 IHC) GNAS FISH FISH Thyroid (16 Molecular, 2 FISH, 1 IHC) ALK RET TERT Promoter FISH RET FISH Options for Customization Add-Ons Any genes in the 54-gene Myeloid Disorders Profile may be added to any of the Hematologic Diseases Profiles. Any genes in the 48-gene Precision Profile for Solid Tumors may be added to any of the other Solid Tumor Profiles. Results of testing for added genes will be included in the comprehensive NeoTYPE report for that Profile. Tech-Only FISH This option is available to pathology clients who want to perform the professional components of any FISH tests within a Profile. These clients should order the component FISH tests as tech-only in combination with the molecular portion of the Profile. NeoGenomics Laboratories 7
Ordering Information Specimen options: Peripheral blood Bone marrow aspirate Fresh tissue FFPE slides or block TAT: 10-22 days (varies by Profile) Billing: NeoGenomics offers institutional and third-party billing. New tests are in development. Sign up at www.neogenomics.com to be notified. NeoGenomics Laboratories is a specialized oncology reference laboratory providing the latest technologies, testing partnership opportunities, and interactive education to the oncology and pathology communities. We offer the complete spectrum of diagnostic services in molecular testing, FISH, cytogenetics, flow cytometry, and immunohistochemistry through our nation-wide network of CAP-accredited, CLIA-approved laboratories. Committed to research as the means to improve patient care, we provide Pharma Services for pharmaceutical companies, in vitro diagnostic manufacturers, and academic scientist-clinicians. We promote joint publication with our client physicians. NeoGenomics welcomes your inquiries for collaborations. Please contact us for more information. 12701 Commonwealth Dr., Suite 9 Fort Myers, FL 33913 Phone: 866.776.5907/ Fax: 239.690.4237 neogenomics.com 2017 NeoGenomics Laboratories, Inc. All Rights Reserved. All other trademarks are the property of their respective owners. Rev. 030117